Company profile
Khiron Life Sciences Corp.
OTC: KHRNF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#629 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 36
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ market scale, growth stability
Methodology →Revenue TTM
$12.7M
Rev growth YoY (TTM)
+36.8%
Net income (FY)
-$26.4M
Employees
310
as of 2026-08-30
Market cap
$2.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.2M12.8M CAD2021
Net income-$26.4M-33.1M CAD2021
Operating income-$15.8M-19.8M CAD2021
Total assets$33.3M42.3M CAD2021
Liabilities$7.1M8.9M CAD2021
Equity$26.3M33.3M CAD2021
Revenue trend
FY2017 – FY2021 · USD
FY17
FY18
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Khiron Life Sciences Corp.’s revenue?
Khiron Life Sciences Corp. booked $10.2M in FY2021 revenue, growing 71% year over year — faster than most Healthcare companies we track, at a -258.9% net margin.
Peers · Healthcare
XOMA Royalty Corp.75B+TScan Therapeutics, Inc.39DAlpha Cognition Inc39DZenas BioPharma, Inc.33DJanux Therapeutics, Inc.54DSyros Pharmaceuticals, Inc.——Key facts
CEOAlvaro Francisco Torres
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: KHRNF
Employees310
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.